In current practice, NAT indications have extended to comprise patients with high-risk early-stage disease, especially Human epidermal growth factor receptor 2 (HER2)-amplified and triple-negative breast carcinomas (TNBCs) [3, 4]. Here, ERBB2 is linked to triple-negative breast carcinoma.